Epysqli is used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia ...

Teva Pharmaceuticals (TEVA) and Samsung Bioepis (SSNLF) announced the availability of EPYSQLI in the U.S. EPYSQLI is a biosimilar to Soliris ...

EPYSQLI ® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, ...

UCB, a global biopharmaceutical company, today announced it will present 24 abstracts from its expansive neurology portfolio, regarding rare epilepsies Dravet syndrome (DS) and Lennox-Gastaut syndrome ...

Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those ...

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

This CME program is designed to enhance neurologists' understanding and management of generalized myasthenia gravis (gMG ... surrounding neonatal Fc receptor (FcRn) inhibitors, including their ...

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis (MG) and initial results from Period 1 of a mid-stage study of the ...

Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of Daily ... baseline in MG-ADL in acetylcholine receptor antibody positive (AChR+ ...